Welcome to Galleon, a leader in the pharmaceutical treatment of sleep apnea and related breathing-control disorders
There are unmet medical needs for both parenteral and oral products to control the rate, rhythm and output of respiration.We used sophisticated pharmacology, medicinal chemistry and drug-discovery tools to achieve scientific breakthroughs in creating potential drug treatments for breathing-control conditions. We are creating a pipeline of drugs for sleep apnea, one of the most recognized breathing control disorders for which there is currently no pharmaceutical treatment.
Our current product pipeline reflects recent advances in neurobiology, molecular physiology and pharmacology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials.
Well-Defined Markets: Galleon is focused on breathing control conditions, in particular sleep apnea. Sleep apnea is a challenging condition for physicians to manage, both in-patient and in the...Learn More
Novel Products: Galleon’s product pipeline addresses the needs of both acute and chronic care patients. Our lead product, GAL-021, recently completed a clinical proof-of-concept study...Learn More
Award Winning Science: Galleon’s novel science was recently recognized by the American Society of Anesthesiology (ASA) and The Society of Anesthesia and Sleep Medicine (SASM)…Learn More